Q32 Bio Inc. announced that it has entered into agreement with existing and new investors for a private placement of $42 million November 16, 2023. The transaction included participation from new investors, Bristol-Myers Squibb Company, CU Healthcare Innovation Fund, L.P., managed by, University of Colorado School of Medicine, Endowment Arm, Agent Capital, returning investors, OrbiMed Advisors LLC, Atlas Venture L.P., Abingworth LLP, Acorn Bioventures, Oup Management Co., LLC, Sanofi Ventures and other undisclosed investors.